← Eichor
Study identifier: NCT06649240 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke

Condition: Ischemic Stroke · Small Vessel Cerebrovascular Disease · Cholesterol, LDL  ·  Sponsor: Seoul National University Hospital

PhaseNA
Planned participants4016
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

Lipid-lowering therapy constitutes a cornerstone of secondary prevention in ischemic stroke; however, current stroke guidelines remain deficient in providing optimal target low-density lipoprotein (LDL)-cholesterol levels tailored to the stroke subtypes. Most clinical trials on LDL-cholesterol management have not differentiated between stroke subtypes or have primarily focused on large artery atherosclerosis (LAA) stroke, leaving a gap in evidence for managing LDL-cholesterol in other stroke subtypes, e.g., small vessel occlusion (SVO) stroke. While hypertension is the leading risk factor for SVO strokes, the link between elevated LDL-cholesterol and SVO stroke is also recognized. Establishing optimal LDL-cholesterol targets for SVO stroke would significantly enhance secondary prevention strategies and improve patient outcome. Thus, the investigators aim to compare intensive versus standard lipid-lowering in patients with SVO stroke. SVO70 is a multicenter, prospective, randomized, open, blinded-endpoint clinical trial. Adult participants with objectively confirmed SVO stroke within 180 days of randomization will be included. Exclusion criteria include those with predefined LDL-cholesterol targets for other conditions, statin contraindications, or women who are pregnant, breastfeeding, or planning pregnancy during the study period. Eligible participants will be randomized 1:1 to target LDL-cholesterol \<70 mg/dL (intensive group) or 90-110 mg/dL (standard group). The trial pl…

This description comes directly from the study's public registry record.

Talk to the study team

Wookjin Yang, MD, PhD  ·  +82-70-4352-2482  ·  ywj_2002@naver.com

Seung-Hoon Lee, MD, PhD  ·  +82-2-2072-1014

Always discuss trial participation with your own doctor first.

Locations (46)

Korea University Ansan HospitalAnsan, South KoreaRecruiting
Hallym University Sacred Heart HospitalAnyang, South KoreaRecruiting
Pusan National University HospitalBusan, South KoreaRecruiting
Gyeongsang National University Changwon HospitalChangwon, South KoreaRecruiting
Samsung Changwon HospitalChangwon, South KoreaRecruiting
Chungbuk National University HospitalCheongju-si, South KoreaRecruiting
Hallym University Chuncheon Sacred Heart HospitalChuncheon, South KoreaRecruiting
Kangwon National University HospitalChuncheon, South KoreaRecruiting
Daegu Catholic University Medical CenterDaegu, South KoreaRecruiting
Keimyung University Dongsan Medical CenterDaegu, South KoreaRecruiting
Kyungpook National University Chilgok HospitalDaegu, South KoreaRecruiting
Kyungpook National University HospitalDaegu, South KoreaRecruiting

+ 34 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06649240